- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02074046
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer
Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Pancreatic Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the Pancreatic Cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the Pancreatic Cancer patient using a similar protocol as investigators reported .
Aim 1: To demonstrate, in vitro, the relative cellular anti-Pancreatic Cancer CSC immunity induced by Pancreatic Cancer CSC-DC primed cytotoxic T cells.
Aim 2: To determine, in vitro, specific binding and lysis of Pancreatic Cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with Pancreatic Cancer CSC-DC.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Biological treatment center in Fuda cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas. The site of the primary lesion should be confirmed endoscopically, radiologically, or surgically to be in the pancreas.
2. Patients must be deemed unresectable due to involvement of critical vasculature, adjacent organ invasion, presence of metastasis, or other medical condition making surgical resection unfavorable.
3. Patients must have a primary or metastatic lesion measurable in at least one dimension by RECIST criteria within 4 weeks prior to entry of study .
4. More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
5. Life expectancy of >3 months. 6. Karnofsky performance status >70%. 7. The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation):
- Hemoglobin: Within normal range according to institutional standards;
- Absolute leukocyte count: Within normal range according to institutional standards;
- Absolute lymphocyte count: Within normal range according to institutional standards;
- Platelet count: Within normal range according to institutional standards;
- Alanine aminotransferase: ≤ 2.5 x Upper Limit of Normal (ULN);
- Aspartate aminotransferase: ≤ 2.5 x ULN;
- Total bilirubin: ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN;
- Serum creatinine: 1.5 x ULN;
- Calculated creatinine clearance: > 50 mL/min . 8. Age >18 years. 9. No history of autoimmune diseases. 10. Ability to understand the study protocol and a willingness to sign a written informed consent document.
Exclusion Criteria:
- 1. Patients receiving anticoagulation therapy. 2. Patients who have received prior gemcitabine or radiation therapy to the pancreatic bed 3. Patients receiving any other investigational agents. 4. Patients with known brain metastases will be excluded because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse effects.
5. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
6. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 7. level 3 hypertension; 8. severe coronary disease; 9. myelosuppression; 10. respiratory disease; 11. brain metastasis; 12. chronic infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: non-cancer stem cell vaccine
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
|
|
Experimental: giving low dose vaccine
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
|
|
Experimental: giving middle dose vaccine
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
|
|
Experimental: giving high dose vaccine
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
Time Frame: up to 3 months
|
up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
Time Frame: 1 month
|
1 month
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The dose of CSC vaccine
Time Frame: up to 3 months
|
up to 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP-001
- 201401 (Other Grant/Funding Number: The research fund of Fuda cancer hospital in Guangzhou)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Pancreas
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Joseph J. CullenNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaboratorsActive, not recruitingAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Newcastle-upon-Tyne Hospitals NHS TrustMedtronicCompletedPancreas Adenocarcinoma | Chronic Pancreatitis | Pancreas Cancer | Pancreas Neoplasm, BenignUnited Kingdom
-
Peking Union Medical College HospitalRecruitingPancreas Cancer | Solid Pseudopapillary Tumor of the PancreasChina
-
Baylor Research InstituteUnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas CancerUnited States
-
BioXcel Therapeutics IncIQVIA BiotechWithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); BioMed Valley Discoveries, IncTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Hospital del MarUnknownPancreatic Adenocarcinoma | Pancreas Cancer | Pancreas Neoplasm | Benign Pancreas TumorSpain
Clinical Trials on cancer stem cell vaccine
-
Fuda Cancer Hospital, GuangzhouUniversity of MichiganCompletedNeoplasms,ColorectalChina
-
Fuda Cancer Hospital, GuangzhouUniversity of MichiganCompleted
-
Fuda Cancer Hospital, GuangzhouUniversity of MichiganCompleted
-
Fuda Cancer Hospital, GuangzhouUniversity of MichiganCompleted
-
NewLink Genetics CorporationNational Cancer Institute (NCI)CompletedLung Neoplasms | Adenocarcinoma of Lung | Non-small Cell Carcinoma | Squamous Cell Carcinoma | Large Cell CarcinomaUnited States
-
Talaris Therapeutics Inc.Northwestern UniversityNo longer availableRenal FailureUnited States
-
University of Michigan Rogel Cancer CenterCompletedSarcoma | Neuroblastoma | Wilm's TumorUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedReduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationChronic Lymphocytic LeukemiaUnited States
-
China Medical University HospitalUnknownIschemia | Ischemic Stroke | Brain Ischemia | Infarction, Middle Cerebral Artery | Ischaemic Cerebral InfarctionTaiwan
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico